Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Trastuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Similar to the parental antibody Trastuzumab, glycoengineered ADCC-enhancement Trastuzumab works by targeting HER2 / neu receptors on cancer cells. In the normal body, the HER2 protein receptor is displayed on the cell surface and sends signals by inducing cell division and reproduction, thus indicating normal cell growth. In some cancerous breast tissues, HER2 is excessive (HER2 / neu overexpressed), triggering excessive cell division and reproduction. Trastuzumab attaches to the HER2 receptor to inhibit cell proliferation, prevent further cancer growth and slow cancer progression. It can also work by stimulating immune mechanisms - antibody-dependent cellular cytotoxicity (ADCC).
It is suitable for treating early HER2-positive early breast cancer or metastatic breast cancer that substantially overexpresses HER2. Approved for gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic adenocarcinoma of the gastro-esophageal junction, provided that these cancers overexpress HER2.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.